Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 3/2010

01-09-2010 | Review Article

New antiviral therapies for chronic hepatitis C

Authors: Tatsuo Kanda, Fumio Imazeki, Osamu Yokosuka

Published in: Hepatology International | Issue 3/2010

Login to get access

Abstract

Chronic hepatitis C is an important health issue worldwide. The current standard therapy is based on a combination of pegylated-interferon (pegIFN) and ribavirin (RBV), but this treatment leads to only ~50% sustained virological response (SVR) in patients with HCV genotype 1 and high viral loads, who were mostly null-responders or relapsers. Among HCV genotypes other than HCV genotype 1, especially HCV genotype 4 patients show only 40–70% SVR by this treatment. Although new drugs also depend on the combination of pegIFN and RBV, it appears that these drugs improve not only rapid virological response (RVR) but also early virological response, leading to SVR in these patients. In the near future, we predict higher SVR rates in chronic hepatitis C patients treated with these new drugs.
Literature
1.
2.
Hoofnagle JH, Seef LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444–2451PubMedCrossRef
3.
Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Eringer S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy. Ann Intern Med 1997;127:875–881PubMed
4.
Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374PubMedCrossRef
5.
Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832–836PubMedCrossRef
6.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954–960PubMedCrossRef
7.
Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VH. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007;14:721–729PubMed
8.
Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in native patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004;9:491–497PubMed
9.
Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006;45:204–213PubMedCrossRef
10.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Datz C, Vogel W, Loschenberger K, Steindl-Munda P, Austrian Hepatitis Study Group. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010;138:503–512PubMedCrossRef
11.
Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2009;30:342–355PubMedCrossRef
12.
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, HALT-C Trial Investigator. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429–2441PubMedCrossRef
13.
Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD, Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470–477PubMedCrossRef
14.
Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163–168PubMedCrossRef
15.
Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P, Latino Study Group. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009;360:257–267PubMedCrossRef
16.
Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265–2271PubMedCrossRef
17.
Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260–1269PubMedCrossRef
18.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401PubMedCrossRef
19.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109PubMedCrossRef
20.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–1109PubMedCrossRef
21.
Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis C and HIV Cohort Studies. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure—a genome-wide association study. Gastroenterology 2010;138:1338–1345
22.
Carr C, Hollinger FB, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver Int 2007;67:1957–1974
23.
Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroentrol Hepatol 2005;43:954–960
24.
Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009;150:528–540PubMed
25.
Reddy KR, Shiffman ML, Rodriguez-Torres MR, Abdurakhmanov D, Bakulin I, Silva GF, Cheinquer H, Rabbia M, Depamphilis J, McKenna M, Harrison SA. Standard versus higher induction doses of peginterferon alfa-2a (40kd) and/or higher ribavirin (rbv) in hcv G1 patients with high viral load and body weight ≥85 kg: final results of the progress study. Hepatology 2009;50:330A
26.
Thompson AJV, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009;16:377–387PubMedCrossRef
27.
Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010;17:77–90PubMedCrossRef
28.
Basu A, Kanda T, Beyene A, Saito K, Meyer K, Ray R. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 2007;81:3933–3941PubMedCrossRef
29.
Watashi K, Shimotohono K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007;17:245–252PubMedCrossRef
30.
Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci USA 2009;106:5342–5347PubMedCrossRef
31.
Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Najes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llias-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186–189PubMedCrossRef
32.
Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 2007;133:1144–1155PubMedCrossRef
33.
Kwo P, Lawitz E, McCone J, Schiff ER, Vierling J, Pound D, Davis M, Galati J, Gordon S, Ravendhran N, Rossaro L, Anderson F, Jacobson I, Rubin R, Koury K, Brass C, Chaudhri E, Albrecht J. HCV SPRINT-1 Final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C. J Hepatol 2009;50:S4CrossRef
34.
Kwo P, Lawitz E, McCone J, Schiff ER, Vierling JM, Pound D, Davis M, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Boparai N, Chaudhri EI, Brass CA, Albrecht JK. High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with boceprevir (BOC) combination therapy. Hepatology 2009;50:331A
35.
Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997–1002PubMedCrossRef
36.
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–1838PubMedCrossRef
37.
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliers M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839–1850PubMedCrossRef
38.
McHuchison JG, Manns MP, Muir A, Terrault N, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Bsharat M, George S, Adda N, Di Bisceglie AM. PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Hepatology 2009;50:334A
39.
Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, Vangeneugden T, Picchio G, Beumont-Mauviel M. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-c patients: interim results of study C209. J Hepatol 2009;50:S22CrossRef
40.
Manns M, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, Dusheiko G, Flisiak R, Meyvisch P, Lenz O, Sekar V, van’t Klooster G, Simmen K, Verloes R. OPERA-1 trial: interim analysis of safety and antiviral activity of tmc435 in treatment-naive genotype 1 HCV patients. J Hepatol 2009;50:S7CrossRef
41.
Marcellin P, Reesink H, Berg T, Cramp M, Flisiak R, Van Vlierberghe H, Verloes R, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J Hepatol 2009;50:S385CrossRef
42.
Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Wiedmann R, Hwang P, Quirk E, Silber J, Lee A. MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. J Hepatol 2009;50:S384CrossRef
43.
Kukolj G, Benhamou Y, Manns MP, Bourlière M, Pol S, Schuchmann M, Cartier M, Huang D, Lagacé L, Steinmann G, Stern JO. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J Hepatol 2009;50:S347CrossRef
44.
Pasquinelli C, Eley T, Villegas C, Sandy K, Mathias E, Wendelburg P, Liao S, McPhee F, Scola PM, Sun LQ, Marbury TC, Lawitz E, Goldwater R, Rodriguez-Torres M, DeMicco MP, Ababa M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology 2009;50:411A
45.
Wang P, Chun BK, Rachakonda S, Du J, Khan N, Shi J, Stec W, Cleary D, Ross BS, Sofia MJ. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem 2009;74:6819–6824PubMedCrossRef
46.
47.
Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WR. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008;52:4356–4369PubMedCrossRef
48.
Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, de Bondt H, Vos AM, Berke J, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, Vandyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA, Fanning GC. 1a/1b subtype profiling of non-nucleoside polymerase inhibitors of hepatitis C virus. J Virol 2010;84:2923–2934PubMedCrossRef
49.
Pockros P, Rodriguez-Torres M, Villano S, Maller E, Chojkier M. A phase 2, randomized study of HCV-796 in combination with pegylated-interferon (PEG) plus ribavirin (RBV) versus PEG plus RBV in hepatitis C virus genotype-1 infection. J Hepatol 2009;50:S7–S8CrossRef
50.
Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JF, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson M, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marison T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008;48:1769–1778PubMedCrossRef
51.
Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631–639PubMedCrossRef
52.
Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antivir Res 2008;77:177–185PubMedCrossRef
53.
Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25:991–1002PubMedCrossRef
54.
Sulkowski MS, Zeuzem S, Lawitz E, Grigorescu M, Tice AD, Rustgi VK, Rodriguez-Torres M, Lurie Y, Cianciara J, Bacon BR, Bain VG, Kryczka W, Pulkstenis E, Subramanian GM, McHutchison JG. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment naïve patients with chronic hepatitis C genotype 1. Hepatology 2009;50:333A
55.
Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, Rodriguez-Torres M, Bain V, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C. J Hepatol 2009;50:S378CrossRef
56.
Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Goke B, Diepolder H, Auernhammer CJ. SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL28A and IL-29. Biochem Biophys Res Commun 2005;331:543–548PubMedCrossRef
57.
Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008;283:30079–30089PubMedCrossRef
58.
Dodds MG, Hausman DF, Miller DM. Viral kinetic modeling during treatment with interferon lambda-1A in genotype 1 chronic hepatitis C patients. J Hepatol 2009;50:S342–S343CrossRef
59.
Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. Therapeutic vaccine IC41 as late add-onto standard treatment in patients with chronic hepatitis C. Vaccine 2009;27:5142–5151PubMedCrossRef
60.
Fibas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 2010;28:2397–2407CrossRef
61.
Lin Y, Kwon T, Polo J, Coates S, Crawford K, Dong C, Wininger M, Hall J, Selby M, Coit D, Medina-Selby A, McCoin C, Ng P, Drane D, Chien D, Han J, Vajdy M, Hougton M. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82:7492–7503PubMedCrossRef
62.
Habersetzer F, Baumert TF, Soll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456–462PubMed
63.
Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP. Therapeutic vaccination of chronic hepatitis C nonresponder patients with peptide vaccine IC41. Gastroenterology 2008;134:1385–1395PubMedCrossRef
64.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Frisch J, Klaude CS. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343–4353PubMedCrossRef
65.
McHutchison JG, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Lee WM, Pockros P, Chasen RM, Vierling JM, Lawitz E, Kugelmas M, Tsai N, Armstrong BR, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin improves end of treatment response at 48 weeks versus peg-IFN/ribavirin in naïve genotype 1 chronic HCV patients. Hepatology 2009;50:LB15
66.
Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res 2008;77:56–63PubMedCrossRef
67.
Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2α via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009;137:1827–1835PubMedCrossRef
68.
Rossignol JF, Kabil SM, El-Gohary Y, Keeffe EB. Randomized double blind placebo-controlled trial of nitazoxanide in the treatment of patients with chronic hepatitis C genotype 4. J Hepatol 2008;48:S311–S312CrossRef
69.
Rossignol JF, Kabil SM, El-Gohary Y, Keeffe EB. Randomized controlled trial of nitazoxanide–peginterferon–ribavirin, nitazoxanide–peginterferon and peginterferon–ribavirin in the treatment of patients with chronic hepatitis C genotype 4. J Hepatol 2008;48:S30CrossRef
70.
Shiffman M, Ahmed A, Jacobson I, Pruitt R, Keeffe E. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (nr) with chronic hcv genotype 1: week 28 interim analysis. J Hepatol 2009;50:S385–S386CrossRef
71.
Bacon B, Shiffman M, Lim J, Berman A, Rustgi V, Keeffe E. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR. J Hepatol 2009;50:S381CrossRef
72.
Tauskela JS. MitoQ—a mitochondria-targeted antioxidant. IDrugs 2007;10:399–412PubMed
73.
Gane EJ, Orr DW, Weilert F, Keogh GF, Gibson M, Murphy MP, Smith RA, Lockhart MM, Frampton CM, Taylor KM. Phase II study of the mitochondrial antioxidant mitoquinone for hepatitis C. J Hepatol 2008;48:S318CrossRef
74.
Watashi K. Alisporivir, a cyclosporine derivate that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr Opin Investig Drugs 2010;11:213–224PubMed
75.
Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567–572PubMed
76.
Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M. Suppression of hepatitis C virus replication by cyclosporine A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031–1041PubMedCrossRef
77.
Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111–122PubMedCrossRef
78.
Goto K, Watashi K, Inoue D, Hijikata M, Shimotohno K. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci 2009;100:1943–1950PubMedCrossRef
79.
Ke J, Lawitz E, Rozier R, Marbury T, Nguyen N, Serra D, Dole K, Praestgaard J, Huang M, Evans T. Safety, and tolerability of nim811, a novel cyclophilin inhibitor for hcv, following single and multiple ascending doses in healthy volunteers and hcv-infected patients. J Hepatol 2009;50:S229CrossRef
80.
Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 2009;10:860–870PubMed
81.
Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Craxí A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010;51:1158–1167
82.
Abu-Mouch S, Fireman Z, Jarchovsky J, Assy N. The beneficial effect of vitamin D combined peg interferon and ribavirin for chronic HCV infection. Hepatology 2009;50:LB20
83.
Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791–796PubMedCrossRef
84.
Kanda T, Basu A, Steele R, Wakita T, Ryerse JS, Ray R, Ray RB. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 2006;80:4633–4639PubMedCrossRef
85.
Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005;79:13963–13973PubMedCrossRef
86.
Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TJ, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623–626PubMedCrossRef
87.
Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294–9299PubMedCrossRef
88.
Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, Ray R. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 2002;76:2150–158PubMedCrossRef
89.
Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–113PubMedCrossRef
90.
Iwasaki Y, Shiratori Y, Hige S, Nishiguchi S, Takagi H, Onji M, Yoshida H, Izumi N, Kohgo Y, Yamamoto K, Sato N, Shibuya A, Saito H, Suzuki K, Kaneko S, Moriyama M, Omata M. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009;3:468–479CrossRef
91.
Ichikawa T, Nakao K, Miyaaki H, Eguchi S, Takatsuki M, Fujimoto M, Akiyama M, Mimura S, Ozawa E, Shibata H, Takeshita S, Kanematsu T, Eguchi K. Hepatitis C virus kinetics during the first phase of pegylated interferon-α-2b with ribavirin therapy in patients with living donor liver transplantation. Hepatol Res 2009;39:856–864PubMedCrossRef
92.
Tseng KH, Chen LH, Chen CY, Chang TT, Chou AL, Wu IC, Cheng PN. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon alfa-2b. Hepatol Res 2009;39:539–545PubMedCrossRef
93.
Kanda T, Steele R, Ray R, Ray RB. Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect. J Virol 2007;81:669–676PubMedCrossRef
94.
Griffin S, Stgelais C, Owsianka AM, Patel AH, Rowlands D, Harris M. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of p7 ion channel. Hepatology 2008;48:1779–1790PubMedCrossRef
95.
Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T. Cyclosporin A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009;50:1638–1645PubMedCrossRef
96.
Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008;26:1019–1027PubMedCrossRef
97.
Belon CA, High YD, Lin TI, Pauwels F, Frick DN. Mechanism and specificity of a symmetrical benzimidazole-phenyl-carboxamide helicase inhibitor. Biochemistry 2010;49:1822–1832
98.
Nettles E, Chien C, Chung E. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 2008;48:LB12
99.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–593PubMedCrossRef
100.
Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008;28:9–16PubMedCrossRef
101.
Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496–504PubMedCrossRef
102.
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124–134PubMedCrossRef
103.
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609–2617PubMedCrossRef
104.
El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005;100:2447–2452PubMedCrossRef
105.
Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F, Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007;14:460–467PubMedCrossRef
106.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006;24:593–600PubMedCrossRef
107.
Nguyen NH, Vutien P, Garcia RT, Trinh H, Nguyen H, Nguyen K, Levitt B, Nguyen MH. Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010 (in press)
108.
Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198:808–812PubMedCrossRef
Metadata
Title
New antiviral therapies for chronic hepatitis C
Authors
Tatsuo Kanda
Fumio Imazeki
Osamu Yokosuka
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 3/2010
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9193-3

Other articles of this Issue 3/2010

Hepatology International 3/2010 Go to the issue

Review Article

Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration

Original Article

Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma

Original Article

Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan

Original Article

Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy

Original Article

Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population

Original Article

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits